Literature DB >> 23922356

Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.

Jae Seok Lee1, Sun Min Lim, Sun Young Rha, Jae Kyung Roh, Yong Jin Cho, Kyu Ho Shin, Woo Ik Yang, Se Hoon Kim, Hyo Song Kim.   

Abstract

BACKGROUND: We investigated the diagnostic and prognostic usefulness of anaplastic lymphoma kinase (ALK) expression in Asian rhabdomyosarcoma (RMS) patients. PATIENTS AND METHODS: A total of 38 RMS tissue samples were collected over a 14-year period (1998-2012). ALK protein expression and gene copy number were analysed by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).
RESULTS: Ten of the 38 RMS patients (26.3%) showed positive ALK protein expression. ALK protein expression was predominantly positive in alveolar RMS (ARMS) compared with embryonal RMS (ERMS) (80% vs 20%, p=0.03). ALK protein expression was statistically associated with ARMS histology, metastatic disease at diagnosis, and primary trunk site. In FISH analysis, no translocations were detected and ALK gene copy number gain was observed more frequently in ARMS than in ERMS (40% vs 17%). The ALK-positive group showed inferior overall survival (OS) compared with ALK-negative group (p=0.014) for both alveolar and embryonal RMS patients. In multivariate analysis, positive ALK expression was an independent prognostic factor for OS (p=0.02; HR, 3.1; 95% CI 1.2 to 8.3). There was a significant strong positive correlation between ALK gene copy number and protein expression (Spearman's r<0.001, r=0.77).
CONCLUSIONS: We demonstrated that ALK protein expression is statistically associated with ARMS histology, metastatic disease at diagnosis and primary trunk site. Additionally, ALK expression was an independent prognostic factor for worse survival. There was a strong correlation between IHC and FISH. Further studies are needed to evaluate the potential diagnostic and therapeutic role of ALK expression in RMS.

Entities:  

Keywords:  FISH; IMMUNOCYTOCHEMISTRY; rhabdomyosarcoma

Mesh:

Substances:

Year:  2013        PMID: 23922356     DOI: 10.1136/jclinpath-2013-201655

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.

Authors:  Dalia Elsers; Doaa F Temerik; Alia M Attia; A Hadia; Marwa T Hussien
Journal:  J Pathol Transl Med       Date:  2021-05-11

2.  Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.

Authors:  Min Hwan Kim; Soohyeon Lee; Ja Seung Koo; Kyung Hae Jung; In Hae Park; Joon Jeong; Seung Il Kim; Seho Park; Hyung Seok Park; Byeong-Woo Park; Joo-Hang Kim; Joohyuk Sohn
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 3.  ALK: a tyrosine kinase target for cancer therapy.

Authors:  Vijaykumar R Holla; Yasir Y Elamin; Ann Marie Bailey; Amber M Johnson; Beate C Litzenburger; Yekaterina B Khotskaya; Nora S Sanchez; Jia Zeng; Md Abu Shufean; Kenna R Shaw; John Mendelsohn; Gordon B Mills; Funda Meric-Bernstam; George R Simon
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-01

4.  Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

Authors:  Anke E M van Erp; Melissa H S Hillebrandt-Roeffen; Laurens van Houdt; Emmy D G Fleuren; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

5.  High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.

Authors:  P Bonvini; A Zin; R Alaggio; B Pawel; G Bisogno; A Rosolen
Journal:  Br J Cancer       Date:  2013-10-22       Impact factor: 7.640

6.  Identification of ALK gene alterations in urothelial carcinoma.

Authors:  Joaquim Bellmunt; Shamini Selvarajah; Scott Rodig; Marta Salido; Silvia de Muga; Irmgard Costa; Beatriz Bellosillo; Lillian Werner; Stephanie Mullane; André P Fay; Robert O'Brien; Jordi Barretina; André E Minoche; Sabina Signoretti; Clara Montagut; Heinz Himmelbauer; David M Berman; Philip Kantoff; Toni K Choueiri; Jonathan E Rosenberg
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

7.  PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma.

Authors:  Keisuke Akaike; Yoshiyuki Suehara; Shinji Kohsaka; Takuo Hayashi; Yu Tanabe; Saiko Kazuno; Kenta Mukaihara; Midori Toda-Ishii; Taisei Kurihara; Youngji Kim; Taketo Okubo; Yasuhide Hayashi; Kazuya Takamochi; Fumiyuki Takahashi; Kazuo Kaneko; Marc Ladanyi; Tsuyoshi Saito
Journal:  Oncotarget       Date:  2018-05-18

8.  A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Authors:  Dina Mönch; Sabine Bode-Erdmann; Jörg Kalla; Jörn Sträter; Carsten Schwänen; Roger Falkenstern-Ge; Siegfried Klumpp; Godehard Friedel; German Ott; Claudia Kalla
Journal:  Oncotarget       Date:  2018-04-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.